News AZ sells rights to three older drugs to Covis for $350m AstraZeneca has agreed to sell rights to three older drugs for asthma and rhinitis to Covis Pharma for at least $350 million.
News BMS eyes filings for idiopathic pulmonary fibrosis drug Bristol Myers Squibb has reported phase 3 results with a new drug for idiopathic pulmonary fibrosis that could open the door to regulatory filings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
